News
#PFE #AGMB — Pfizer Signs Up to $2.63 Billion CAR-T Licensing Deal With Starna Therapeutics | ThinkSabio
Nov 18, 2026 · ThinkSabio Inc
Pfizer has signed a licensing agreement worth up to $2.63 billion with Starna Therapeutics to develop next-generation in vivo CAR-T treatments. The deal gives Pfizer exclusive rights outside Greater China to three preclinical programs targeting autoimmune diseases.
🔹 Key Highlights
Total Deal Value: Up to $2.63 billion.
Upfront Payment: $330 million.
Milestone Payments: Up to $2.3 billion in development and commercial milestones, plus royalties.
Pipeline Access: Exclusive rights outside Greater China to three preclinical in vivo CAR-T programs.
Target Areas: Programs are focused on autoimmune diseases.
Technology Access: The agreement includes access to Starna's RNA-based CAR-T technology for immunology and oncology.
Expansion Options: Pfizer has options to expand licensing rights into Greater China.
💡 Why It Matters
The agreement expands Pfizer's interest in next-generation cell therapies beyond traditional oncology applications into autoimmune diseases. In vivo CAR-T technology aims to generate CAR-T cells directly inside the body, potentially changing how these treatments are developed and delivered. However, the programs remain preclinical, making clinical validation and development timelines key risks.
🚀 Start Your 7-Day FREE ThinkSabio Trial
https://www.thinksabio.com/
ThinkSabio — Stocks Simplified
Share this post
💬 Comments
Loading comments…
Leave a comment
